Trial Profile
A multicentre observational study for the long term follow up of subjects that have been treated with enadenotucirev during interventional clinical trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Enadenotucirev (Primary)
- Indications Breast cancer; Colorectal cancer; Ovarian cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Akamis Bio; PsiOxus Therapeutics
- 05 Jan 2023 According to an Akamis Bio media release, PsiOxus Therapeutics has changed its name to Akamis Bio.
- 10 Apr 2022 Status changed from recruiting to completed.
- 05 Dec 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.